1. After this meeting, do you agree that IL5 inhibition is a relevant mechanism of action (MOA) in targeting eosinophilic diseases? *
2. After this meeting, do you agree that anti-IL5 treatment has shown sufficient efficacy to reduce the use of oral corticosteroids and improve outcomes in patients with relapsing/refractory EGPA? *
3. What will be your reasons to consider using anti-IL5 biologic in patients with EGPA/HES? (Multiple answers are allowed) *
4. After this meeting, I am confident to start collaborating with my peers from other specialties to treat my patients with EGPA/HES. *
5. What is the best part of the meeting? (Multiple answers are allowed) *